veltuzumab + epratuzumab

Veltuzumab + epratuzumab is a combination of two humanized monoclonal antibodies targeting B-cell surface antigens. Veltuzumab targets CD20, a protein expressed on the surface of B-cells, and is structurally similar to rituximab but with a single amino acid difference that results in slower off-rates and improved complement-dependent cytotoxicity in some lymphoma models. Epratuzumab targets CD22, another B-cell specific protein, and modulates B-cell receptor signaling by intensifying the inhibitory role of CD22, leading to reduced activation and proliferation of B cells. The combination has been investigated for use in relapsed or refractory aggressive lymphomas and other autoimmune diseases such as systemic lupus erythematosus. Both agents are designed to deplete or modulate pathogenic B cells through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and immunomodulation[1][2][3][6].

Other names

veltuzumab and epratuzumab